title: [The changes of coagulation and fibrinolysis function on hypoxia adaptation mechanism].
abstract: OBJECTIVE
  To determine their Antithrombin-III (AT-III), Plasminogen (PLG), D-Dimer (DD), tissue-Plasminogen Activator (t-PA), Plasminogen Activator Inhibitor (PAI), Fibrinogen (Fg) and alpha2-Plasmin, inhibitor (alpha2-PI), when 40 subjects entered to high altitude, and compared with healthy flatlander.
  
  
  RESULTS
  At high altitude (3 700 m, 5 380 m) the AT-III abd t-PA were lower significantly than that of the flatlander (1 400m) (P < 0.05 or P < 0.01). The higher altitude subjects enter, the lower count will take (P < 0.01), and with the longer stay time, there was a higher count (P < 0.05 or P < 0.01). The 7th day at high altitude, PLG. DD. PAI. alpha2-PI and Fg were much higher than the flatlander's (P < 0.05 or P < 0.01), and with the higher elevation, there were higher datas, and with the longer stay time, there were lower datas (P < 0.05 or P < 0.01). Compare the a half of year at 3 700m with the flatlands, the results isn't discrepant (P > 0.05).
  
  
  CONCLUSIONS
  There is a coagulation-function disorder at high altitude, the results shows that coagulation and fibrinolysis are activated and fibrinolysis is inhibited yet, so the coagulation-fibrinolysis balance is destroyed. This effects lead to a hypercoagulation and hypo fibrinolysis state.
authors.affiliation: The18th Hospital of PLA, Xinjiang Yecheng 844900, China.
authors.forename: J H
authors.initials: JH
authors.lastname: Cui
authors.forename: X Z
authors.initials: XZ
authors.lastname: Zhang
authors.forename: Y Z
authors.initials: YZ
authors.lastname: Xie
authors.forename: X M
authors.initials: XM
authors.lastname: Zhou
authors.forename: Z D
authors.initials: ZD
authors.lastname: Ha
mesh_terms: D000293:Adolescent; D000328:Adult; D000531:Altitude; D000990:Antithrombin III / Q000032:analysis; D001777:Blood Coagulation / Q000502:physiology*; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D005341:Fibrinolysin / Q000032:analysis; D005342:Fibrinolysis / Q000502:physiology*; D006801:Humans; D000860:Hypoxia; D008297:Male; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis; D010959:Tissue Plasminogen Activator / Q000032:analysis; D055815:Young Adult; D000979:alpha-2-Antiplasmin / Q000032:analysis
chemical_list: D005338:Fibrin Fibrinogen Degradation Products; D017395:Plasminogen Activator Inhibitor 1; D000979:alpha-2-Antiplasmin; C036309:fibrin fragment D; C037742:plasmin-plasmin inhibitor complex; D000990:Antithrombin III; D005340:Fibrinogen; D010959:Tissue Plasminogen Activator; D005341:Fibrinolysin